Author argues SLS is overvalued and likely to be diluted into a discount sale, and plans to add to his bearish position when it pumps.
SLS — SHORT The author argues SLS is overvalued and likely to fall because the market misinterprets its clinical data and the recent catalyst is 'BS'; ongoing dilution practices and poor financials will erode value before any buyout, which he expects to happen at a discount. He says any estimate of $60 is delusional and the stock is trading at a premium. He plans to add to his bearish position when the stock pumps.
I even plan to double down on my position against SLS (hopefully when the price pumps a little more).
This Reddit post, published January 03, 2026, features u/Sensitive-Radish-292 discussing SLS. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Sensitive-Radish-292 · Tickers: SLS